Long-term Study of DSP-5423P in Patients With Schizophrenia <Phase 3>

Trial Profile

Long-term Study of DSP-5423P in Patients With Schizophrenia <Phase 3>

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Blonanserin (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Sumitomo Dainippon Pharma
  • Most Recent Events

    • 19 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 21 Jul 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Jul 2017.
    • 08 Jul 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top